Expression of the Arabidopsis CGS1 gene that codes for cystathionine ␥-synthase is feedback regulated at the step of mRNA stability in response to S-adenosyl-L-methionine (AdoMet). A short stretch of amino acid sequence, called the MTO1 region, encoded by the first exon of CGS1 itself is involved in this regulation. Here, we demonstrate, using a cell-free system, that AdoMet induces temporal translation elongation arrest at the Ser-94 codon located immediately downstream of the MTO1 region, by analyzing a translation intermediate and performing primer extension inhibition (toeprint) analysis. This translation arrest precedes the formation of a degradation intermediate of CGS1 mRNA, which has its 5 end points near the 5 edge of the stalled ribosome. The position of ribosome stalling also suggests that the MTO1 region in nascent peptide resides in the ribosomal exit tunnel when translation elongation is temporarily arrested. In addition to the MTO1 region amino acid sequence, downstream Trp-93 is also important for the AdoMet-induced translation arrest. This is the first example of nascent peptide-mediated translation elongation arrest coupled with mRNA degradation in eukaryotes. Furthermore, our data suggest that the ribosome stalls at the step of translocation rather than at the step of peptidyl transfer.[Keywords: S-adenosyl-L-methionine; translation arrest; mRNA stability; MTO1 region; cystathionine ␥-synthase; feedback regulation] Supplemental material is available at http://www.genesdev.org. Cystathionine ␥-synthase (CGS; EC 2.5.1.48) catalyzes the first committed step of methionine biosynthesis in higher plants (Matthews 1999) and is encoded by the CGS1 gene in Arabidopsis thaliana (gene ID At3g01120; Kim and Leustek 1996). Expression of the CGS1 gene is regulated by negative feedback at the step of mRNA stability in response to methionine application in Arabidopsis. When wild-type calli were treated with methionine, the amount of full-length CGS1 mRNA was decreased, and a short CGS1 RNA species formed that is truncated at its 5Ј region. This 5Ј-truncated RNA species is likely an intermediate of CGS1 mRNA degradation. The mto1 mutants of Arabidopsis, which carry single amino acid sequence alterations within the first exon of CGS1, are deficient in this regulation and overaccumulate soluble methionine (Chiba et al. 1999). A short stretch of amino acid sequence, termed the MTO1 region, which is encoded within CGS1 exon 1 and covers the mto1 mutation sites, is involved in this process (Ominato et al. 2002). Since CGS1 exon 1 acts in cis, we proposed that this regulation occurs during translation, when the nascent polypeptide and its mRNA are in close proximity (Chiba et al. 1999;Suzuki et al. 2001). In support of this idea, the regulation is abolished by application of a translation inhibitor (Lambein et al. 2003).CGS1 exon 1-mediated post-transcriptional regulation was reproduced in an in vitro translation system using wheat germ extract, and S-adenosyl-L-methionine (AdoMet), a direct metabolite of methionine...

Cystathionine ␥-synthase, the first committed enzyme of methionine biosynthesis in higher plants, is encoded by the CGS1 gene in Arabidopsis thaliana. We have shown previously that the stability of the CGS1 mRNA is negatively regulated in response to methionine application [Chiba, Y., Ishikawa, M., Kijima, F., Tyson, R. H., Kim, J., Yamamoto, A., Nambara, E., Leustek, T., Wallsgrove, R. M. & Naito, S. (1999) Science 286, 1371-1374]. To determine whether methionine itself is the effector of the CGS1 exon 1-mediated posttranscriptional regulation, we carried out transfection experiments. The results suggested that, rather than methionine, Sadenosyl-L-methionine (AdoMet), or one of its metabolites, acts as the effector of this regulation. To further identify the actual effector, we exploited the wheat germ in vitro translation system. The effects of various metabolites and analogs of AdoMet were tested by using RNA carrying a CGS1 exon 1-reporter fusion. These tests identified AdoMet as the effector of this regulation. Sadenosyl-L-ethionine, an analog of AdoMet, also had effector activity. A. thaliana mto1 mutants, which are deficient in this regulation, showed a much reduced response to AdoMet in vitro, with a leaky allele showing a less reduced response. RNA translated in vitro in the presence of AdoMet contained a 5-truncated RNA species, similar to the one that we previously suggested was an in vivo degradation intermediate of CGS1 mRNA. Together, the results show that the basic reactions of CGS1 exon 1-mediated posttranscriptional regulation occur in the wheat germ in vitro translation system, and that AdoMet acts as the effector. C ystathionine ␥-synthase (CGS; EC 4.2.99.9) catalyzes the first committed step of methionine biosynthesis in higher plants (1) (Fig. 1), which is considered to be the key regulatory step in methionine biosynthesis (2-5). Unlike many of the key-step enzymes in metabolic pathways, CGS is not an allosteric enzyme (2). CGS is encoded in Arabidopsis thaliana by the CGS1 gene (gene ID At3g01120, GenBank accession no. AB010888) (6, 7). We have previously shown (8) that CGS1 expression involves feedback regulation at the level of mRNA stability in response to methionine application in vivo. A. thaliana mto1 mutants are deficient in this feedback regulation, and overaccumulate CGS1 mRNA, CGS protein, and soluble methionine. Seven independently isolated mto1 mutants were found to carry single-base changes within the first exon of CGS1, giving rise to amino acid sequence changes (8, 9).Transient and transgenic expression experiments using CGS1 exon 1-reporter fusions (8, 10) showed that the exon 1 coding sequence of CGS1 is necessary and sufficient for its posttranscriptional regulation, in response to exogenous application of methionine. In vitro mutagenesis of CGS1 exon 1 revealed that it is its amino acid sequence that has a role in this regulation. We have identified a stretch of 11-13 amino acid residues, termed the MTO1 region, located Ϸ80 residues from the N terminus of CGS, and coverin...

Cystathionine gamma-synthase (CGS) catalyses the first committed step of methionine biosynthesis in higher plants. CGS is encoded by the CGS1 gene in Arabidopsis. Stability of CGS1 mRNA is down-regulated in response to methionine application and the exon 1-coding region of CGS1 itself is necessary and sufficient for this regulation. mto1 (for methionine overaccumulation) mutants of Arabidopsis, which carry single-amino-acid sequence alterations within CGS1 exon 1, are deficient in this regulation and overaccumulate methionine. Since CGS1 exon 1 acts in cis during this regulation, we have proposed a model that the regulation occurs during translation of CGS1 mRNA when the nascent polypeptide of CGS and its mRNA are in close proximity. In fact, application of the translation inhibitor cycloheximide abolished this regulation in vivo. This model predicts that the regulation can be reproduced in an in vitro translation system. Studies using the in vitro translation system of wheatgerm extract have indicated that S-adenosylmethionine, a direct metabolite of methionine, is the effector of this regulation. A 5'-truncated RNA species, which is a probable degradation intermediate of CGS1 mRNA in vivo, was also detected in vitro, suggesting that the wheatgerm in vitro translation system reflects the in vivo regulation.

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome. Although the major BCR/ABL transcript is present in majority of CML patients, the minor BCR/ABL transcript is rarely reported as an additional chromosomal abnormality related to the progression of CML. We describe the case of a 37-year-old woman who had CML and pain in the extremities. She was diagnosed with lymphoid blast crisis of CML on the basis of the following findings: presence of promyelocytes, myelocytes, and metamyelocytes in peripheral blood smear; detection of major and minor BCR/ABL transcripts by polymerase chain reaction analysis; proliferation of lymphoblastic cells with abnormal B-cell phenotype; and aberrant expression of myeloid antigens in the bone marrow. The patient underwent one course of idarubicin and cytosine arabinose therapy combined with imatinib followed by daunorubicin/cyclophosphamide plus vincristine and prednisone/L: -asparaginase (DNR/COP/L: -ASP) therapy, high-dose cytosine arabinose, and CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone). Subsequently, the patient underwent high-dose chemotherapy (total body irradiation and cyclophosphamide) followed by allogeneic bone marrow stem cell transplantation from a human leukocyte antigen (HLA)-matched unrelated donor. After these treatments, the patient was disease-free for 19 months. Our case suggests that these treatments may be feasible, safe, and effective for the treatment of patients with blast crisis CML expressing the minor BCR/ABL transcript.

No abstract